Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia

Archives of General Psychiatry

Volumn 57, Issue 12, 2000, Pages 1139-1147

  Umbricht, D ^a   Schmid, L ^a   Koller, R ^a   Vollenweider, F X ^a   Hell, D ^a   Javitt, D C ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AMNESIA; ARTICLE; BRAIN FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; MALE; NEUROTRANSMISSION; NORMAL HUMAN; PATHOPHYSIOLOGY; PERCEPTION DEAFNESS; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE;

EID: 0033663587     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.12.1139     Document Type: Article

References (87)

1. The neuropsychology of schizophrenia: What, when, where, how?
2. Impaired attention, genetics, and the pathophysiology of schizophrenia
3. Cognitive event-related potential correlates of schizophrenia
4. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia
5. Sensorimotor gating and schizophrenia: Human and animal model studies
6. Gating and habituation of the startle reflex in schizophrenic patients
7. What are the functional consequences of neurocognitive deficits in schizophrenia?
8. Neurocognitive impairment in schizophrenia and how it affects treatment options
9. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia
10. Behavioral lifetime of human auditory sensory memory predicted by physiological measures
11. Auditory sensory ('echoic') memory dysfunction in schizophrenia
12. Impaired precision, but normal retention, of auditory sensory ('echoic') memory information in schizophrenia
13. Word and tone working memory deficits in schizophrenia
14. Brain potential evidence for an auditory sensory memory deficit in schizophrenia
15. Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study
16. Stimulus-vergleichsprozesse bei psychotischen jugendlichen mit paranoiden und nicht paranoiden symptomen: 'Mismatch Negativity' deutet auf differenzierte beeintrachtigungen hin
17. Mismatch negativity: An index of a preattentive processing deficit in schizophrenia
18. Effects of clozapine on auditory event-related potentials in schizophrenia
19. Effects of risperidone on auditory event-related potentials in schizophrenia
20. Deficits in auditory and visual context-dependent processing in schizophrenia: Defining the pattern
21. Schizophrenic deficits in the processing of context: A test of a theoretical model
22. Context-processing deficits in schizophrenia: Converging evidence from three theoretically motivated cognitive tasks
23. Glutamate receptor dysfunction and schizophrenia
24. Recent advances in the phencyclidine model of schizophrenia
25. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
26. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
27. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers
28. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
29. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
30. Seroquel restores sensorimotor gating in phencyclidine-treated rats
31. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
32. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
33. Metabolic hypedrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)
34. Intrahippocampal administration of a glycine site antagonist impairs working memory performance of rats
35. Blockade of NMDA receptors located at the dorsomedial prefrontal cortex impairs spatial working memory in fats
36. NMDA but not AMPA receptor antagonists impair the delay-interposed radial maze performance of rats
37. Effects of intrahippocampal injections of N-methyl-D-aspartate receptor antagonists and scopolamine on working and reference memory assessed in rats by a three-panel runway task
38. Enhanced N-methyl-D-aspartate function reverses working memory failure induced by blockade of group I metabotropic glutamate receptors in the rat hippocampus
39. Detection of stimulus deviance within primate primary auditory cortex: Intracortical mechanisms of mismatch negativity (MMN) generation
40. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: Implications for schizophrenia
41. Observations on the psychomimetic effects of Sernyl
42. Observations on the action of Sernyl: A new psychotropic drug
43. Study of a new schizophrenomimetic drug: Sernyl
44. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
45. Pharmacokinetics of ketamine in man
46. Pharmacotogical effects of Cl-581, a new dissociative anesthetic in man
47. Ketamine: An update on the first twenty-five years of clinical experience
48. The measurement of handedness
49. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples
50. Anchoring the brief psychiatric rating scale: An aid to improve reliability
51. The modified mini-mental state (3MS) examination
52. Auditory mismatch negativity in schizophrenia: Topographic evaluation with a high-density recording montage
53. Prefrontal cortex and context processing in medication-naive first-episode patients with schizophrenia
54. Demonstration of mismatch negativity in the monkey
55. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
56. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
57. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: Evidence on reversible up-regulation by typical neuroleptics
58. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
59. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia
60. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging
61. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia
62. The effects of a subanaethetic dose of ketamine on human selective attention
63. Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNm) elicited by sound changes
64. Mismatch negativity to auditory stimulus change recorded directly from the human temporal cortex
65. A distributed cortical network for auditory sensory memory in humans
66. Lesions of frontal cortex diminish the auditory mismatch negativity
67. Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10
68. Fragments of ACTH affect electrophysiological signs of controlled stimulus processing in humans
69. Electrophysiological indices of information processing in methylphenidate responders
70. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
71. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures
72. The glutamatergic basis of human alcoholism
73. Low dose of ethanol suppresses mismatch negativity of auditory event-related potentials
74. Dose-related effect of alcohol on mismatch negativity and reaction time performance
75. Mismatch negativity subcomponents and ethyl alcohol
76. Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide
77. The chiral forms of ketamine as probes for NMDA-receptor function in humans
78. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors
79. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
80. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
81. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release
82. Investigations into the neurobiology of information processing deficits in schizophrenia
83. Effects of NMDA-antagonists and 5-HT2A-agonists on generation of MMN in human volunteers